Navigation Links
Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
Date:3/13/2008

y alters cellular signaling required for cell survival. RAV12 is highly efficacious in human colon, gastric, and pancreatic tumor xenograft models in vivo and has been found to be well tolerated in repeat dose primate toxicology studies.

About Pancreatic Cancer

Adenocarcinoma of the pancreas is a major unmet medical need and represents the fourth leading cause of cancer death in the US. Approximately 34,000 new cases of pancreatic cancer are reported in the US each year. Five-year survival rates are approximately 1% to 2%. Gemcitabine was approved for use in pancreatic cancer a decade ago, but little advance in treatment outcomes has occurred since.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast and ovarian cancer.

On November 12, 2007, Raven and VaxGen Inc. (OTC: VXGN.PK), a biopharmaceutical company, announced that their respective boards of directors unanimously approved a definitive merger agreement. The merger is expected
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
2. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
7. Inclinix Announces New Patent for Expert System Platform
8. Genzyme Announces Presentation of New Positive Data on Carticel(R)
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 Insulet Corporation (NASDAQ: PODD ... its OmniPod ® Insulin Management System, today announced ... 30, 2015. The Company also announced that it will ... results and conference call from Thursday, July 30, as ... Revenue Highlights: , Preliminary second ...
(Date:7/29/2015)... 2015  Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 2015 on Wednesday, August 5, 2015, after the close of ... executive officer, will host a conference call to review the ... Time (PT). The press release and a ... through a link that is posted on the home page ...
(Date:7/29/2015)... , July 29, 2015  Ascendis Pharma A/S ... that applies its innovative TransCon technology to address significant ... a conference call on July 30, 2015, at 9:00 ... a Phase 2 pediatric study of once-weekly TransCon Growth ... the top-line results before the market opens on July ...
Breaking Medicine Technology:Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time 2
... 11, 2012   OTC Markets Group Inc. (OTCQX: ... provides the world,s largest electronic marketplace for broker-dealers to ... (OTCQX: DIAGF; TSX: SDI), a Phase III company ... severe sepsis and septic shock, is now trading on ...
... PRINCETON, N.J., Jan. 11, 2012 NewCardio, Inc., ... announced today that a biotechnology pharmaceutical company, which ... therapeutics for disorders of the central nervous system ... solution, for an upcoming Thorough QT trial. Fully ...
Cached Medicine Technology:Spectral Diagnostics, Inc. Joins OTCQX 2Biotechnology Pharmaceutical Company Selects NewCardio's QTinno for Thorough QT Trial 2Biotechnology Pharmaceutical Company Selects NewCardio's QTinno for Thorough QT Trial 3
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences faculty, students and ... Games, the largest sports and humanitarian event in the world this year and the ... Games, held July 25 through August 2, 2015, benefited from the participation of WesternU’s ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... On July ... $2 billion in taxpayer money to fund the state’s large prison system, which has ... with the highest rates of incarceration. In light of President Obama’s recent reduction of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to ... nonsurgical treatment designed specifically for the elimination of excess tissue under the chin, ... in the state of Wisconsin to offer this innovative treatment. , Developed by Kythera ...
(Date:7/30/2015)... Angeles, CA (PRWEB) , ... July 30, 2015 , ... ... gummy smiles, including lip lowering, gum contouring and surgery, as well as the patented ... technical artistry that has made him popular with many patients from around the world. ...
(Date:7/30/2015)... ... July 30, 2015 , ... The New Jersey Innovation Institute ... Department of Health, has received a $2.9 million grant from the Office of ... of Health and Human Services (HHS). NJII will help the Department of Health ...
Breaking Medicine News(10 mins):Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2
... ORANGE PARK, Fla., Feb. 19 Transitionz Wellness,Boutique ... child or adult, who,is a cancer survivor, is ... who is trying to get well, and we ... some of the best products and services,including wigs, ...
... (Feb. 19, 2008) -- A longstanding puzzle in neurodevelopment may ... by scientists at Weill Cornell Medical College says they have ... neuron,s long, skinny axon affect gene transcription back in the ... evidence of a transcription factor -- proteins that influence gene ...
... resolve issues, improve health, PITTSBURGH, Feb. 19 ... weeks for an appointment with an eye specialist ... edema and other vision,disorders. To address the urgency ... (POS) recently launched an initiative with,Highmark to offer ...
... Converge in Chicago, CHICAGO, Feb. 19 The ... Who: The Chicago Dental Society (CDS) recently polled ... dental habits, adults seeking,braces, and how the current presidential ... annual Midwinter Meeting, one of the largest,displays of dental ...
... LLC,today released notice of the final implementation schedule ... Part A and Part B,fee-for-service Medicare claims in ... reiterated the availability of its Jurisdiction 4 (J4),Web ... of the implementation,to health care providers in those ...
... essential for women who find menopause an intense and ... where health services are patchy or inaccessible. Thats the ... of the Journal of Advanced Nursing. , ... a predominantly rural Canadian province where a large proportion ...
Cached Medicine News:Health News:Transitionz Wellness Boutique Launches with Grand Opening Discounts 2Health News:Scientists shed light on long-distance signaling in developing neurons 2Health News:Scientists shed light on long-distance signaling in developing neurons 3Health News:Express Screening Process Aims to Put Diabetics on the Fast Track to Better Health 2Health News:Express Screening Process Aims to Put Diabetics on the Fast Track to Better Health 3Health News:TrailBlazer Announces Final Medicare Administrative Contractor Schedule for Claims Processing in Four States 2Health News:Menopausal women need better health care and community support in rural areas 2Health News:Menopausal women need better health care and community support in rural areas 3
The clear choice for surgery, foreign body removal,and other delicate work.,Oculus binocular loupes come in 1.8x magnification with a 30 cm working distance--or 2.5x magnification with a choice ...
Eyeglass Loupe 3x-5x made with precision optical glass. Ideal for any detail work....
... designed for computer operators who require ... placed at different heights and distanced ... Card is printed two sided- black ... and uses two type sizes to ...
Near PT test card/child recog/ playing cards 5 1/2" X 8"....
Medicine Products: